Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 11, 2010, Pages 5878-5887

  Ufret Vincenty, Rafael L ^a   Aredo, Bogale ^a   Liu, Xinran ^a   McMahon, Anne ^a   Chen, Peter W ^a   Sun, Hui ^b,c   Niederkorn, Jerry Y ^a   Kedzierski, Wojciech ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; MESSENGER RNA; NUCLEASE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DNA FLANKING REGION; DRUSEN; ELECTRON MICROSCOPY; EYE; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LAMINAR FLOW; LIVER; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINA CELL; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHIMERA; COMPLEMENT C3; COMPLEMENT FACTOR H; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENOTYPE; LIVER; MACULAR DEGENERATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; POSTERIOR EYE SEGMENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER;

EID: 79955050748     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4457     Document Type: Article

References (54)

1. Friedman DS, O'Colmain BJ, Munöz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
2. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
3. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291-306.
4. Zarbin MA. Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol. 1998;8:199-206.
5. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32-42.
6. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res. 2010;29:95-112.
7. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
8. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308: 385-389.
9. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
10. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
11. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-7232.
12. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
13. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005;123:774-782.
14. Ferguson TA, Apte RS. Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol. 2008;30:111-119.
15. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2009;93:610-613.
16. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168-2173.
17. Lee AY, Brantley MA Jr. CFH and LOC387715/ARMS2 genotypes and antioxidants and zinc therapy for age-related macular degeneration. Pharmacogenomics. 2008;9:1547-1550.
18. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology. 2008;115:1019-1025.
19. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damageinduced inflammation initiates age-related macular degeneration. Nat Med. 2008;14:194-198.
20. Malek G, Johnson LV, Mace BE, et al. Apolipoprotein E alleledependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci U S A. 2005;102:11900-11905.
21. Tuo J, Bojanowski CM, Zhou M, et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:3827-3836.
22. Ambati J, Anand A, Fernandez S, et al. An animal model of agerelated macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med. 2003;9:1390-1397.
23. Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002;31:424-428.
24. Simonet WS, Bucay N, Lauer SJ, Taylor JM. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem. 1993;268:8221-8229.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- ΔΔC(T)) method. Methods. 2001;25:402-408.
26. Yu J, Wiita P, Kawaguchi R, et al. Biochemical analysis of a common human polymorphism associated with age-related macular degeneration. Biochemistry. 2007;46:8451-8461.
27. Xu H, Chen M, Manivannan A, Lois N, Forrester JV. Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. Aging Cell. 2008;7:58-68.
28. Anderson DH, Ozaki S, Nealon M, et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol. 2001;131:767-781.
29. Demberg T, Pollok-Kopp B, Gerke D, Götze O, Schlaf G. Rat complement factor H: molecular cloning, sequencing and quantification with a newly established ELISA. Scand J Immunol. 2002; 56:149-160.
30. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41:355-367.
31. Espinosa-Heidmann DG, Suner IJ, Catanuto P, Hernandez EP, Marin-Castano ME, Cousins SW. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci. 2006;47: 729-737.
32. Cousins SW, Marin-Castanö ME, Espinosa-Heidmann DG, Alexandridou A, Striker L, Elliot S. Female gender, estrogen loss, and sub-RPE deposit formation in aged mice. Invest Ophthalmol Vis Sci. 2003;44:1221-1229.
33. Fujihara M, Bartels E, Nielsen LB, Handa JT. A human apoB100 transgenic mouse expresses human apoB100 in the RPE and develops features of early AMD. Exp Eye Res. 2009;88:1115-1123.
34. Coffey PJ, Gias C, McDermott CJ, et al. Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A. 2007;104:16651-16656.
35. Sjoberg AP, Trouw LA, Clark SJ, et al. The factor H variant associated with age-related macular degeneration (His-384) and the nondisease- associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem. 2007;282: 10894-10900.
36. Prosser BE, Johnson S, Roversi P, et al. Structural basis for complement factor H linked age-related macular degeneration. J Exp Med. 2007;204:2277-2283.
37. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A. 2006;103:17456-17461.
38. Kezic J, McMenamin PG. Differential turnover rates of monocytederived cells in varied ocular tissue microenvironments. J Leukoc Biol. 2008;84:721-729.
39. Hadziahmetovic M, Dentchev T, Song Y, et al. Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest Ophthalmol Vis Sci. 2008;49:2728-2736.
40. Luhmann UF, Robbie S, Munro PM, et al. The drusen-like phenotype in aging Ccl2 knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages. Invest Ophthalmol Vis Sci. 2009;50:5934-5943.
41. Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 2006;3:e310.
42. Kelly J, Ali Khan A, Yin J, Ferguson TA, Apte RS. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest. 2007;117:3421-3426.
43. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3586-3592.
44. Cousins SW, Espinosa-Heidmann DG, Csaky KG. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol. 2004;122:1013-1018.
45. Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman lecture. Ophthalmology. 1993;100:1519-1535.
46. Cousins SW, Espinosa-Heidmann DG, Alexandridou A, Sall J, Dubovy S, Csaky K. The role of aging, high fat diet and blue light exposure in an experimental mouse model for basal laminar deposit formation. Exp Eye Res. 2002;75:543-553.
47. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000;192:1353-1364.
48. Laine M, Jarva H, Seitsonen S, et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol. 2007;178:3831-3836.
49. Ormsby RJ, Ranganathan S, Tong JC, et al. Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:1763-1770.
50. Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem. 2010;285:1053-1065.
51. Bíró A, Rovó Z, Papp D, et al. Studies on the interactions between C-reactive protein and complement proteins. Immunology. 2007; 121:40-50.
52. Hakobyan S, Harris CL, van den Berg CW, et al. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem. 2008;283:30451-30460.
53. Okemefuna AI, Stach L, Rana S, Buetas AJ, Gor J, Perkins SJ. C-reactive protein exists in an NaCl concentration-dependent pentamer- decamer equilibrium in physiological buffer. J Biol Chem. 2010;285:1041-1052.
54. Papers of the Week: Factor H and CRP complement each other. J Biol Chem. 2010;285:e99905.